Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer Hehui FangDoudou HuangXiaoxiang Guan Review 13 December 2017 Pages: 287 - 297
Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis E. A. UnderwoodP. A. RochonM. C. Tierney Review 20 December 2017 Pages: 299 - 310
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition E. Santana dos SantosS. M. CaputoE. Rouleau Preclinical study 13 December 2017 Pages: 311 - 325
Enrichment of high-grade tumors in breast cancer gene expression studies M. van SeijenA. L. MooyaartE. H. Lips Preclinical study Open access 18 December 2017 Pages: 327 - 335
Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer Y. F. YuY. WangH. R. Yao Clinical trial Open access 29 November 2017 Pages: 337 - 348
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer Alexios MatikasSara MargolinJonas Bergh Clinical trial Open access 30 November 2017 Pages: 349 - 355
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy B. PistilliT. PluardC. Saura Clinical trial 02 December 2017 Pages: 357 - 364
99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis Jiwei WangTie FanTao Ouyang Clinical trial 06 December 2017 Pages: 365 - 370
A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer Mohammed F. K. IbrahimJohn HiltonMark Clemons Clinical trial 06 December 2017 Pages: 371 - 379
A single institution experience with palbociclib toxicity requiring dose modifications Jun GongMay ChoJoanne Mortimer Clinical trial Open access 07 December 2017 Pages: 381 - 387
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study Jie XieJun CaoXi-chun Hu Clinical trial 11 December 2017 Pages: 389 - 399
CD14+ HLA-DR−/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation Lisa SpeiglHelen BurowChristopher Shipp Clinical trial 11 December 2017 Pages: 401 - 411
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer Erik J. BlokJudith R. KroepOn Behalf of the IDEAL Study Group Clinical trial Open access 12 December 2017 Pages: 413 - 420
Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy Jonna K. van VulpenMartina E. SchmidtKaren Steindorf Clinical trial 12 December 2017 Pages: 421 - 431
Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work Claire FalandryIvan KrakowskiGilles Freyer Clinical trial 14 December 2017 Pages: 433 - 441
Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study Zhiyu XiaKathy B. BaumgartnerAvonne E. Connor Epidemiology 30 November 2017 Pages: 443 - 455
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer T. ReinertM. DebiasiC. H. Barrios Epidemiology 30 November 2017 Pages: 457 - 465
Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors Sarah J. O. NomuraYi-Ting HwangJudy Huei-yu Wang Epidemiology 11 December 2017 Pages: 467 - 479
Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors Sarah J. O. NomuraYi-Ting HwangJudy Huei-yu Wang Correction 11 January 2018 Pages: 481 - 482
Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy Wentao LiCarol Chi-Hei KwokLap Ah Tse Epidemiology 11 December 2017 Pages: 483 - 493
Worse survival after breast cancer in women with anorexia nervosa Annet BensFotios C. PapadopoulosLene Mellemkjær Epidemiology 12 December 2017 Pages: 495 - 500
Analysis of breast cancer in young women in the Department of Defense (DOD) database Alexandra S. ZimmerKangmin ZhuStanley Lipkowitz Epidemiology 15 December 2017 Pages: 501 - 511
Predictors of survival for breast cancer patients with a BRCA1 mutation Steven A. NarodTomasz HuzarskiJan Lubinski Epidemiology 15 December 2017 Pages: 513 - 521
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy Marilyn L. KwanSong YaoJoan C. Lo Epidemiology 16 December 2017 Pages: 523 - 530
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer Zhe WangJing KongRui Ling Brief Report 28 November 2017 Pages: 531 - 542
Characterization of a novel germline BRCA1 splice variant, c.5332+4delA Ciyu YangSowmya JairamLiying Zhang Brief Report 28 November 2017 Pages: 543 - 550
Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy S. N. HanF. AmantOn behalf of the International Network on Cancer, Infertility and Pregnancy Brief Report 12 December 2017 Pages: 551 - 557
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer Pauline du RusquecClément PalpacuerJean-Sébastien Frenel Brief Report 15 December 2017 Pages: 559 - 566
Genetic variation in TNFα, PPARγ, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort Catherine DugganRichard N. BaumgartnerAnne McTiernan Brief Report 18 December 2017 Pages: 567 - 576
Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017. Alejandra F. Pichilingue-FebresMiguel A. Arias-LinaresRoger V. Araujo-Castillo Letter to the Editor 21 December 2017 Pages: 577 - 578